

FluoroPharma Medical, Inc. (OTCBB: FPMI)

500 Boylston Street
 Suite 1600
 Boston, MA 02116

Share Price	\$0.76
Volume	2.5 k
Shares Outstanding	22,440,894
Market Cap	\$17.06 m
52 Week High	\$2.15
52 Week Low	\$0.56

as of 05/18/2012



Overview

FluoroPharma Medical, Inc. (FPMI) is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to improve patient management by evaluating cardiac disease at the cellular and molecular levels. FluoroPharma is advancing two products in clinical trials for assessment of acute and chronic forms of coronary disease. These agents have been designed to rapidly target myocardial cells within the heart or inflamed plaques within the coronary arteries.

Our Market

Molecular Imaging Market

FluoroPharma's products utilize positron emission tomography (PET) technology, a molecular imaging platform that is growing rapidly due to its inherently superior sensitivity and specificity compared to other imaging options. Molecular imaging fulfills unmet needs in diagnosis and follow-up therapy by enabling visualization, characterization and measurement of biological processes at the molecular and cellular level. Unlike more commonly known imaging modalities – MRI, CT, and Ultrasound– that provide insight into the anatomical manifestation of disease, molecular imaging techniques, such as PET, provide insight into physiology and can detect disease before anatomical manifestation is identified. The market for molecular imaging agents currently exceeds \$1.7 billion annually.

Cardiovascular Market

Disclaimer

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in the computer industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-K and its quarterly reports on Forms 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.

In the US today, symptomatic coronary artery disease (CAD) affects more than 13 million patients and accounts for more than 30% of all deaths. Cardiologists' demand for faster, more accurate diagnostic tools continuously drives the development of non-invasive techniques with increased sensitivity and accuracy for the detection and assessment of acute and chronic CAD. Molecular imaging is currently used in more than 9 million myocardial perfusion imaging (MPI) procedures, the standard test for diagnosing CAD.

Additional Diagnostic Markets

Alzheimer's Disease - As many as 5.2 million people in the United States are living with Alzheimer's and 10 million baby boomers will develop Alzheimer's in their lifetime. Currently, there is no single diagnostic test that proves a person has AD. FluoroPharma is developing new options for early detection and treatment of Alzheimer's, to improve patient care and create new paths for AD management.

Prostate cancer - Prostate cancer is the most frequently diagnosed and second most lethal malignancy among men in the United States. FluoroPharma is developing new compounds to enable earlier and more accurate diagnosis of prostate cancer.

Officers & Directors

David R. Elmaleh, PhD

Chairman, Director and Chief Scientific Advisor

Thijs Spoor

Director, CEO & President

Boyan Goumnerov, MD

COO & Vice President Clinical Trials

Walter Witoshkin

Director

Peter Conti, MD, PhD

Director, Scientific Advisory Board

Lawrence Atinsky

Director

Recent News

Monday, March 19, 2012 - 10:12 AM

[FluoroPharma is Granted Patent Rights for BFPET in Australia, Expanding Global Patent Position](#)

Thursday, March 01, 2012 - 10:15 AM

[FluoroPharma Medical Announces Phase II Study for CardioPET](#)

Friday, January 13, 2012 - 10:54 AM

[FluoroPharma to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference](#)

Friday, December 30, 2011 - 09:46 AM

[FluoroPharma Announces Addition to the Board of Directors](#)

Tuesday, December 20, 2011 - 08:02 AM

[FluoroPharma Announces Aggregate of \\$7M Capital Raise in 2011](#)